Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13809MR)

This product GTTS-WQ13809MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13809MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10172MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ14591MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ5987MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ5096MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ2745MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ11734MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ8374MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ13655MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW